Melfalán Tarbis

Melphalan, the active ingredient in Melfalán Tarbis, is an alkylating agent presented as a sterile injectable for intraarterial and intravenous use. It is employed in the treatment of certain hematologic and solid malignancies, including multiple myeloma, ovarian cancer, malignant melanoma, and chronic lymphocytic leukemia.

GNH USA supplies Melfalán Tarbis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches for clinical use across multiple regions.

Melfalán Tarbis (melphalan) is used in oncology to target rapidly dividing cancer cells across several disease groups.

- Multiple Myeloma: improves response rates and prolongs survival in eligible patients. - Ovarian Cancer: used as part of high‑dose regimens to enhance tumor reduction before surgery. - Malignant Melanoma: employed in selected cases where conventional therapies are insufficient. - Chronic Lymphocytic Leukemia: incorporated into combination protocols to achieve deeper remissions.

Administration of melphalan may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea and vomiting: gastrointestinal upset commonly reported during treatment. - Myelosuppression: decreased white blood cells, red cells and platelets. - Fatigue: generalized tiredness affecting daily activities. - Mucositis: inflammation and ulceration of the oral mucosa. - Alopecia: temporary hair loss during therapy.

Serious or Rare Side Effects: - Secondary malignancies: risk of therapy‑related leukemia or other cancers. - Severe infection: due to profound neutropenia. - Pulmonary fibrosis: rare lung scarring with dyspnea. - Renal toxicity: impaired kidney function in susceptible patients. - Cardiotoxicity: rare cardiac arrhythmias or dysfunction.

Prior to prescribing melphalan, clinicians should evaluate patient-specific factors and follow safety guidelines. - Baseline blood counts: obtain complete blood count to assess marrow reserve. - Renal function: evaluate creatinine clearance before dosing. - Hepatic status: monitor liver enzymes in patients with hepatic impairment. - Pregnancy risk: avoid use in pregnant women unless benefits outweigh risks. - Concomitant myelosuppressive agents: adjust therapy to prevent excessive cytopenia. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Melphalan can interact with other medications, altering its efficacy or toxicity profile.

Major Interactions (Avoid): - High‑dose cyclophosphamide: additive bone‑marrow suppression. - Live vaccines: increased risk of infection due to immunosuppression. - Anticoagulants (warfarin): heightened bleeding risk from mucosal damage.

Moderate Interactions (Monitor Closely): - Allopurinol: may increase melphalan plasma levels. - Azathioprine: combined immunosuppression may exacerbate cytopenias. - NSAIDs: can worsen renal toxicity when used concurrently.